Ipsen at ASCO GI 2018

San Francisco January 18th- 20st #GI18

“Ipsen has a strong presence in oncology at ASCO-GI 2018 with 13 posters dealing with clinical outcomes in pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors and carcinoid syndrome. We and Exelixis, our partner, are excited to announce that the results of the pivotal Phase 3 CELESTIAL Trial of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma will be shared for the first time with the medical community as a late breaking presentation, on January 19th,” said Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen.


Discover the 13 posters and 1 oral presentation that reaffirm Ipsen’s commitment to oncology, its continued investigation into new products and indications.


Follow the ASCO GI 2018 activity on twitter #GI18

Media Tool Kit

Find more information about the investor briefing and the press release issued at ASCO GI 2018.